Invivyd, Inc.
Business
Invivyd, Inc. is a biopharmaceutical company focused on discovery, development and commercialization of monoclonal antibody therapies for prevention and treatment of serious viral infectious diseases, starting with COVID-19. The company's lead product PEMGARDA (pemivibart) received FDA emergency use authorization in March 2024 for pre-exposure prophylaxis of COVID-19 in immunocompromised patients, and VYD2311, a next-generation mAb candidate, is in Phase 3 clinical development. Invivyd is also advancing pipeline candidates for respiratory syncytial virus (RSV) and measles through partnerships with Adimab for antibody discovery and WuXi Biologics for manufacturing.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 53 | 25 | 0 | — | — | |
| Cost of product revenue | 4 | 2 | 0 | — | — | |
| Research and development expense | 38 | 137 | 159 | 179 | 183 | |
| Selling, general and administrative | 67 | 63 | 49 | 47 | 37 | |
| Total operating costs and expenses | 109 | 202 | 213 | 248 | 227 | |
| Loss from operations | −56 | −177 | −213 | −248 | −227 | |
| Other income, net | 3 | 7 | 14 | 7 | 118,000 | |
| Total other income, net | 3 | 7 | 14 | 7 | 118,000 | |
| Net loss | −53 | −170 | −199 | −241 | −227 | |
| Unrealized (loss) gain, net of tax | −36,000 | 8,000 | 259,000 | −264,000 | −8,000 | |
| Comprehensive loss | −53 | −170 | −198 | −242 | −227 | |
| Net loss per share attributable to common stockholders, basic | −0.3 | −1.43 | −1.81 | −2.23 | −5.32 | |
| Net loss per share attributable to common stockholders, diluted | −0.3 | −1.43 | −1.81 | −2.23 | −5.32 | |
| Weighted-average common shares outstanding, diluted | 172 | 119 | 110 | 108 | 43 | |
| Weighted-average common shares outstanding, basic | 172 | 119 | 110 | 108 | 43 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 227 | 69 | 201 | 92 | 542 | |
| Accounts receivable, net | 14 | 11 | 0 | — | — | |
| Prepaid expenses and other current assets | 7 | 20 | 24 | 5 | 25 | |
| Total current assets | 247 | 101 | 225 | 377 | 617 | |
| Inventory | 25 | 26 | 0 | — | — | |
| Property and equipment, net | 1 | 2 | 2 | 2 | 83,000 | |
| Operating lease right-of-use assets | 2 | 1 | 2 | 4 | 2 | |
| Other non-current assets | 110,000 | 34,000 | 175,000 | 191,000 | 3 | |
| Total assets | 277 | 130 | 229 | 383 | 620 | |
| Accounts payable | 14 | 10 | 8 | 2 | 6 | |
| Accrued expenses | 19 | 50 | 41 | 22 | 56 | |
| Operating lease liabilities | 1 | 1 | 1 | 2 | 308,000 | |
| Other current liability | 52,000 | 27,000 | 35,000 | 44,000 | — | |
| Total current liabilities | 34 | 62 | 50 | 25 | 62 | |
| Operating lease liabilities, non-current | 1 | 0 | 722,000 | 2 | 1 | |
| Total liabilities | 35 | 62 | 52 | 27 | 62 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 281,987,033 shares issued and outstanding at December 31, 2025; 119,835,162 shares issued and outstanding at December 31, 2024 | 28,000 | 12,000 | 11,000 | 11,000 | 11,000 | |
| Additional paid-in capital | 1,196 | 970 | 910 | 890 | 850 | |
| Accumulated other comprehensive loss | −41,000 | −5,000 | −13,000 | −272,000 | −8,000 | |
| Accumulated deficit | −955 | −902 | −732 | −533 | −292 | |
| Total stockholders' equity | 242 | 68 | 177 | 356 | 558 | |
| Total liabilities and stockholders' equity | 277 | 130 | 229 | 383 | 620 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −52 | −170 | −199 | −241 | −227 | |
| Stock-based compensation expense | 12 | 20 | 19 | 22 | 18 | |
| Amortization of operating lease right-of-use assets | 1 | 2 | 2 | 421,000 | 0 | |
| Depreciation and amortization expense | 755,000 | 1 | 480,000 | — | — | |
| Other non-cash adjustments | 298,000 | 0 | — | — | — | |
| Accounts receivable | −3 | −11 | 0 | — | — | |
| Inventory | −373,000 | −25 | 0 | — | — | |
| Prepaid expenses and other current assets | 13 | 3 | −19 | 20 | −23 | |
| Other non-current assets | −77,000 | 141,000 | 16,000 | 3 | −3 | |
| Accounts payable | 3 | 2 | 6 | −4 | −2 | |
| Accrued expenses | −31 | 9 | 19 | −35 | 51 | |
| Operating lease liabilities | −1 | −2 | −2 | −475,000 | 0 | |
| Other current liabilities | 23,000 | −8,000 | −10,000 | 44,000 | 0 | |
| Other non-current liabilities | 0 | −700,000 | 700,000 | −5,000 | 1,000 | |
| Net cash used in operating activities | −58 | −170 | −173 | −220 | −185 | |
| Purchases of property and equipment | −155,000 | −140,000 | −615,000 | −2 | −84,000 | |
| Net cash used in investing activities | −155,000 | −140,000 | 281 | −231 | −51 | |
| Proceeds from exercises of stock options | 411,000 | 420,000 | 955,000 | 241,000 | — | |
| Proceeds from issuance of common stock under the employee stock purchase plan | 254,000 | 223,000 | 240,000 | 269,000 | — | |
| Proceeds from at-the-market offering, net of commissions | 33 | 39 | — | — | — | |
| Proceeds from underwritten public offering, net of underwriting discounts and commissions | 183 | 0 | — | — | — | |
| Payments for at-the-market offering costs | −336,000 | −597,000 | — | — | — | |
| Payments for underwritten public offering costs | −633,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 216 | 39 | 1 | 506,000 | 663 | |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 8,000 | 0 | — | — | |
| Net increase (decrease) in cash and cash equivalents | 157 | −131 | 109 | −450 | 427 | |
| Deferred offering costs in accrued expenses | 171,000 | 0 | 273,000 | 0 | — | |
| Deferred offering costs in accounts payable | 88,000 | 71,000 | 0 | — | — | |
| Property and equipment included in accrued expenses | 206,000 | 0 | — | — | — | |
| Property and equipment included in accounts payable | 33,000 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Invivyd, Inc.'s CIK number?
Invivyd, Inc.'s SEC CIK number is 0001832038 (1832038). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Invivyd, Inc.'s SEC filings?
All of Invivyd, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Invivyd, Inc. last report earnings?
Invivyd, Inc. (IVVD) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222762). This is Invivyd, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Invivyd, Inc.'s most recent earnings 8-K?
Invivyd, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222762. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Invivyd, Inc.'s latest earnings 8-K →
Look up any company's CIK number →